MacroGenics, Inc. (NASDAQ:MGNX) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
Thank you. [Operator Instructions] Our first question comes from the line of Debjit Chattopadhyay with H.C. Wainwright. Your line is now open.
Hey. Good afternoon, Scoot and Jim. Thank you for taking my questions. Could you talk to the ability to get to higher doses with MGD019? Is it an engineered lower affinity for CTLA-4 or do you need engagement of both PD-1 x CTLA-4 on the T-cells, which allows you to kind of circumvent the GI tox?
So, Debjit, thanks for the question. The molecule was designed very specifically to get maximum engagement of PD-1. As you remember, this was a tetravalent bispecific molecule. And so, the affinity is a slight increase on PD-1 to get initial engagement with that. And because there are two binding sites for CTLA-4, you get an NVIDIA advantage for then binding the CTLA-4 site. So, in essence, we are getting optimum of recognition of cells that express both receptors. You also see, obviously, binding to cells that express PD-1 alone and occasionally ones that have only CTLA-4, but it was really designed as a way to enhance engagement of these co-expressing cell types.
Could we go higher than 10 mg/kg? It certainly could. But we found, as we will discuss at the ESMO presentation is that we're in a very optimal range. We're seeing clinical responsiveness across multiple doses. What we have previously reported are seeing responses between 3 and 10 mg/kg, number one. And secondly, we saw activation markers associated with these therapeutic responses. So, we see no need to expand the treatment above 10 mg/kg.
Great. Just one follow-up, then. Since you're collecting the biomarker data, are you seeing any differential evolution in either the CD-8 or CD-4 effector T-cell compartment compared to monotherapy PD-1 x CTLA-4?
In the patients?
Yes. In the responders, for example, versus, say, the non-responders?
I can't really address that with regard to the subpopulations at this time, but it's a question we could look on the subsequent analysis.
Great. And just one last follow-up for me, I think. The MGD013 plus marge. Have all the six responses been confirmed since it's been a few -- more than a few weeks since ASCO? Thank you so much.
The unconfirmed responses have now been confirmed, and we've had additional patients that have been enrolled in the trial as we've just described. We expect that we will provide an update on this combination trial at a scientific conference later this year.
Thank you so much and good luck.
Thank you. Our next question comes from the line of Etzer Darout with Guggenheim Securities. Your line is now open.
Hey. This is Paul, on for Etzer. I wanted to ask about MAHOGANY. I understand, I know we're expecting data for Module A of the trial next year. I was wondering, have you measured LAG-3 expression in the Module A patients as a potential kind of hint for what the patient makeup in Module B might look like? And